VEGFA and lung carcinoma: In the present meta-analysis, the combined results of all analyses showed that the pooled OR of nine studies was 1.11 (95% CI: 0.89–1.38, P < 0.001) for the allele model, 1.32 (95% CI: 0.86–2.04, P = 0.047) for the homozygote model, 1.11 (95% CI: 0.86–1.42, P < 0.001) for the heterozygote model, 1.12 (95% CI: 0.87–1.46, P < 0.001) for the dominant model, and 1.25 (95% CI: 0.94–1.65, P = 0.266) for the recessive model, indicating no association between VEGF +936C/T mutation and lung cancer susceptibility (Figure 2).